ID   NCI-H125
AC   CVCL_3968
SY   H125; H-125; NCI-Hut 125; NCI-HUT-125; NCI-HUT 125; HUT-125; HUT 125; HUT125
DR   BTO; BTO:0003010
DR   EFO; EFO_0003116
DR   ATCC; CRL-5801
DR   BioSample; SAMN03471737
DR   cancercelllines; CVCL_3968
DR   CCRID; 1102HUM-NIFDC00022
DR   Cell_Model_Passport; SIDM00106
DR   ChEMBL-Cells; CHEMBL3307888
DR   ChEMBL-Targets; CHEMBL614159
DR   Cosmic; 844593
DR   Cosmic; 877401
DR   Cosmic; 931373
DR   Cosmic; 1028943
DR   Cosmic; 1032431
DR   Cosmic; 1152496
DR   Cosmic; 2560225
DR   GEO; GSM784259
DR   GEO; GSM794271
DR   IARC_TP53; 486
DR   KCLB; 90125
DR   Progenetix; CVCL_3968
DR   PubChem_Cell_line; CVCL_3968
DR   Wikidata; Q54907780
RX   PubMed=1311061;
RX   PubMed=1320893;
RX   PubMed=1845952;
RX   PubMed=2388294;
RX   PubMed=2473086;
RX   PubMed=3335022;
RX   PubMed=3940644;
RX   PubMed=6148444;
RX   PubMed=6270685;
RX   PubMed=6272398;
RX   PubMed=6713399;
RX   PubMed=8806092;
RX   PubMed=9649128;
RX   PubMed=11030152;
RX   PubMed=11369051;
RX   PubMed=12820372;
RX   PubMed=20679594;
RX   PubMed=28196595;
RX   PubMed=29681454;
RX   PubMed=31803961;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African American.
CC   Doubling time: 39 hours (Note=In RPMI 1640 + 10% FBS), 39 hours (Note=In ACL-3), 40 hours (Note=In ACL-3 + BSA) (PubMed=3940644).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238fs (c.714_715ins1); Zygosity=Unspecified (PubMed=1311061; PubMed=12820372).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Unspecified (PubMed=1311061).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: ATCC; CRL-5801; true.
CC   Discontinued: KCLB; 90125; probable.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
ST   Source(s): ATCC; CCRID; PubMed=20679594
ST   Amelogenin: X (ATCC; CCRID)
ST   Amelogenin: X,Y (PubMed=20679594)
ST   CSF1PO: 7
ST   D13S317: 11
ST   D16S539: 5,12
ST   D18S51: 20
ST   D21S11: 29,32.2
ST   D3S1358: 16,17
ST   D5S818: 10
ST   D7S820: 10
ST   D8S1179: 15
ST   FGA: 22,24
ST   Penta D: 11,12
ST   Penta E: 7
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C9133; Lung adenosquamous carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 35
//
RX   PubMed=1311061;
RA   Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D.,
RA   Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D.,
RA   Gazdar A.F.;
RT   "p53 gene mutations in non-small-cell lung cancer cell lines and their
RT   correlation with the presence of ras mutations and clinical
RT   features.";
RL   Oncogene 7:171-180(1992).
//
RX   PubMed=1320893; DOI=10.1159/000163712;
RA   Verbeeck M.A.E., Elands J.P.M., de Leij L.F.M.H., Buys C.H.C.M.,
RA   Carney D.N., Bepler G., Roebroek A.J.M., van de Ven W.J.M.,
RA   Burbach J.P.H.;
RT   "Expression of the vasopressin and gastrin-releasing peptide genes in
RT   small cell lung carcinoma cell lines.";
RL   Pathobiology 60:136-142(1992).
//
RX   PubMed=1845952; DOI=10.1002/1097-0142(19910201)67:3<619::AID-CNCR2820670317>3.0.CO;2-Y;
RA   Broers J.L.V., Mijnheere E.P., Rot M.K., Schaart G., Sijlmans A.,
RA   Boerman O.C., Ramaekers F.C.S.;
RT   "Novel antigens characteristic of neuroendocrine malignancies.";
RL   Cancer 67:619-633(1991).
//
RX   PubMed=2388294; DOI=10.1093/jnci/82.17.1420;
RA   McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C.,
RA   Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.;
RT   "Metabolic activation of 4-ipomeanol in human lung, primary pulmonary
RT   carcinomas, and established human pulmonary carcinoma cell lines.";
RL   J. Natl. Cancer Inst. 82:1420-1426(1990).
//
RX   PubMed=2473086; DOI=10.1242/jcs.91.1.91;
RA   Broers J.L.V., Rot M.K., Oostendorp T., Bepler G., de Leij L.F.M.H.,
RA   Carney D.N., Vooijs G.P., Ramaekers F.C.S.;
RT   "Spontaneous changes in intermediate filament protein expression
RT   patterns in lung cancer cell lines.";
RL   J. Cell Sci. 91:91-108(1988).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3940644;
RA   Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.;
RT   "Growth of cell lines and clinical specimens of human non-small cell
RT   lung cancer in a serum-free defined medium.";
RL   Cancer Res. 46:798-806(1986).
//
RX   PubMed=6148444; DOI=10.1093/jnci/73.4.801;
RA   Morstyn G., Russo A., Carney D.N., Karawya E., Wilson S.H.,
RA   Mitchell J.B.;
RT   "Heterogeneity in the radiation survival curves and biochemical
RT   properties of human lung cancer cell lines.";
RL   J. Natl. Cancer Inst. 73:801-807(1984).
//
RX   PubMed=6270685; DOI=10.1073/pnas.78.7.4591;
RA   Cuttitta F., Rosen S.T., Gazdar A.F., Minna J.D.;
RT   "Monoclonal antibodies that demonstrate specificity for several types
RT   of human lung cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:4591-4595(1981).
//
RX   PubMed=6272398; DOI=10.1126/science.6272398;
RA   Moody T.W., Pert C.B., Gazdar A.F., Carney D.N., Minna J.D.;
RT   "High levels of intracellular bombesin characterize human small-cell
RT   lung carcinoma.";
RL   Science 214:1246-1248(1981).
//
RX   PubMed=6713399;
RA   Rosen S.T., Mulshine J.L., Cuttitta F., Fedorko J., Carney D.N.,
RA   Gazdar A.F., Minna J.D.;
RT   "Analysis of human small cell lung cancer differentiation antigens
RT   using a panel of rat monoclonal antibodies.";
RL   Cancer Res. 44:2052-2061(1984).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=9649128; DOI=10.1038/bjc.1998.361;
RA   Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.;
RT   "Paracrine effects of hepatocyte growth factor/scatter factor on
RT   non-small-cell lung carcinoma cell lines.";
RL   Br. J. Cancer 77:2162-2170(1998).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0;
RA   Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.;
RT   "Molecular cytogenetic analysis of non-small cell lung carcinoma by
RT   spectral karyotyping and comparative genomic hybridization.";
RL   Cancer Genet. Cytogenet. 125:87-99(2001).
//
RX   PubMed=12820372;
RA   Bergqvist M., Brattstrom D., Gullbo J., Hesselius P., Brodin O.,
RA   Wagenius G.;
RT   "p53 status and its in vitro relationship to radiosensitivity and
RT   chemosensitivity in lung cancer.";
RL   Anticancer Res. 23:1207-1212(2003).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//